NCT01249053

Brief Summary

Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

November 24, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 29, 2010

Completed
Last Updated

November 29, 2010

Status Verified

November 1, 2010

First QC Date

November 24, 2010

Last Update Submit

November 26, 2010

Conditions

Lung Adenocarcinoma

Keywords

OPA1lung adenocarcinomasPrognosisExpression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma

Eligibility Criteria

Age25 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Between January 2006 and December 2008, we will retrospectively enroll 100 consecutive LADC patients who were admitted to the Department of Thoracic Surgery of China Medical University Hospital.

You may qualify if:

  • We will collect paraffin blocked resected lung tissue samples from stage I\~IIIa non-small cell lung cancer patients (age, 40\~80 years old) who received lobectomy of the affected lung.

You may not qualify if:

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fang Hsin Yuan

Taichung, 404, Taiwan

RECRUITING

MeSH Terms

Conditions

Adenocarcinoma of Lung

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by Site

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 24, 2010

First Posted

November 29, 2010

Study Start

August 1, 2010

Last Updated

November 29, 2010

Record last verified: 2010-11

Locations

TW(1)